ATE388690T1 - Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen - Google Patents

Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen

Info

Publication number
ATE388690T1
ATE388690T1 AT02775709T AT02775709T ATE388690T1 AT E388690 T1 ATE388690 T1 AT E388690T1 AT 02775709 T AT02775709 T AT 02775709T AT 02775709 T AT02775709 T AT 02775709T AT E388690 T1 ATE388690 T1 AT E388690T1
Authority
AT
Austria
Prior art keywords
agents
nanoparticular
stabilization
formulation
compositions
Prior art date
Application number
AT02775709T
Other languages
English (en)
Inventor
Elaine Merisko-Liversidge
Linden Wei
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25492513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE388690(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE388690T1 publication Critical patent/ATE388690T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT02775709T 2001-09-14 2002-09-13 Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen ATE388690T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/952,032 US20030054042A1 (en) 2001-09-14 2001-09-14 Stabilization of chemical compounds using nanoparticulate formulations

Publications (1)

Publication Number Publication Date
ATE388690T1 true ATE388690T1 (de) 2008-03-15

Family

ID=25492513

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775709T ATE388690T1 (de) 2001-09-14 2002-09-13 Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen

Country Status (11)

Country Link
US (4) US20030054042A1 (de)
EP (2) EP1829530A3 (de)
JP (2) JP2005505568A (de)
AT (1) ATE388690T1 (de)
CA (1) CA2460436C (de)
CY (1) CY1108130T1 (de)
DE (1) DE60225571T2 (de)
DK (1) DK1427395T3 (de)
ES (1) ES2303553T3 (de)
PT (1) PT1427395E (de)
WO (1) WO2003024424A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
CN1558755A (zh) * 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2005120487A2 (de) * 2004-06-11 2005-12-22 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
US20060147515A1 (en) * 2004-12-02 2006-07-06 Zhongzhou Liu Bioactive dispersible formulation
US7727554B2 (en) * 2004-12-21 2010-06-01 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Sustained-release nanoparticle compositions and methods for using the same
WO2006113310A2 (en) * 2005-04-13 2006-10-26 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
MX2007014363A (es) * 2005-05-16 2009-04-15 Elan Pharma Int Ltd Composiciones de liberacion controlada y en forma de nanoparticulas que comprenden una cefalosporina.
US20060280786A1 (en) * 2005-06-14 2006-12-14 Rabinow Barrett E Pharmaceutical formulations for minimizing drug-drug interactions
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
CA2628630A1 (en) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions of lipoxygenase inhibitors
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
EP3141248A1 (de) 2006-03-24 2017-03-15 Auxilium International Holdings, Inc. Stabilisierte zusammensetzungen mit basischen, labilen wirkstoffen
CA2656277A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
AU2007325628A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
KR20150002886A (ko) * 2007-03-07 2015-01-07 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (de) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Verfahren und zusammensetzungen zur behandlung pulmonaler hypertonie
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
CN101945654B (zh) * 2007-12-14 2012-06-27 江崎格力高株式会社 α-硫辛酸纳米颗粒及其制备方法
PE20091550A1 (es) * 2008-01-11 2009-10-03 Cipla Ltd Composicion farmaceutica extruida/granulada en caliente
WO2009113070A1 (en) * 2008-03-12 2009-09-17 Do-Coop Technologies Ltd. Freeze-free method for storage of polypeptides
JP2011520889A (ja) * 2008-05-15 2011-07-21 バクスター・インターナショナル・インコーポレイテッド 安定な医薬製剤
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
WO2011135580A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
WO2011150258A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US9095521B2 (en) 2012-02-02 2015-08-04 Washington University Methods for improving muscle strength
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2016007194A1 (en) * 2014-07-10 2016-01-14 Gerald Lee Wolf Companion nanoparticles for theranosis of macrophage-dependent diseases
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
EP3302423B1 (de) 2015-06-04 2022-05-25 Crititech, Inc. Partikelproduktionssystem und partikelsammelvorrichtung
EP3362042A1 (de) 2015-10-16 2018-08-22 Marinus Pharmaceuticals, Inc. Injizierbare neurosteroidformulierungen mit nanopartikeln
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
WO2017176628A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
BR112019023948A2 (pt) 2017-06-09 2020-06-09 Crititech Inc tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas
EP3615004B1 (de) 2017-06-14 2025-02-19 Crititech, Inc. Verfahren zur behandlung von lungenerkrankungen
JP7792750B2 (ja) 2017-10-03 2025-12-26 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
EP3928772B1 (de) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanopartikuläre zusammensetzung
US12194058B2 (en) * 2021-01-06 2025-01-14 Florida Atlantic University Board Of Trustees Cancer treatment regimen using anti-parasitic compounds and gut microbiome modulating agents

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671750A (en) * 1950-09-19 1954-03-09 Merck & Co Inc Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US3536074A (en) * 1968-03-29 1970-10-27 Alfred Aufhauser Oral administration of a pill,tablet or capsule
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
JPS4932056B1 (de) * 1970-12-22 1974-08-27
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4226248A (en) * 1978-10-26 1980-10-07 Manoli Samir H Phonocephalographic device
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
KR890700586A (ko) * 1987-02-27 1989-04-25 로버어트 에이 아마테이지 피리돈 카르복실산 또는 산유도체를 함유하는 항균제 베타-락탐
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US4951673A (en) * 1988-08-19 1990-08-28 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
JP2687245B2 (ja) * 1989-09-29 1997-12-08 富士写真フイルム株式会社 磁気記録媒体の製造方法
US5250283A (en) * 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
CA2019719A1 (en) * 1990-06-25 1991-12-25 William J. Thompson Mouthwash
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US5434143A (en) * 1991-05-10 1995-07-18 Boron Biologicals, Inc. Pharmaceutical compositions comprising phosphite-borane compounds
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
US5292650A (en) * 1991-10-29 1994-03-08 Eli Lilly And Company Preparation of hapalindole-related alkaloids from blue-green algae
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5498421A (en) * 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
IL128774A (en) * 1994-03-07 2001-05-20 Dow Chemical Co Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5528328A (en) * 1995-02-21 1996-06-18 O'farrill; Dave Camera filter quick release adapter
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
EP0810853B1 (de) * 1995-02-24 2004-08-25 Elan Pharma International Limited Nanopartikel-dispersionen enthaltende aerosole
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5635406A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Stabilized standards and calibrators containing rapamycin and tacrolimus bound to anti-rapamycin and anti-tacrolimus antibodies
KR100400620B1 (ko) * 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
GB9515214D0 (en) * 1995-07-25 1995-09-20 Univ Strathclyde Plant extracts
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5631741A (en) * 1995-12-29 1997-05-20 Intel Corporation Electronic carbon paper
CZ212498A3 (cs) * 1996-01-03 1998-12-16 Smithkline Beecham P. L. C. Karbamoyloxyderiváty mutilinu, způsob výroby a farmaceutický prosředek
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US6239124B1 (en) * 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
EP1068178A1 (de) * 1998-03-05 2001-01-17 Agouron Pharmaceuticals, Inc. Nicht-peptidische gnrh wirkstoffe
WO1999049846A2 (en) * 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
US6228985B1 (en) * 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140373A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6200085B1 (en) * 1999-03-08 2001-03-13 Stuart Gee Transport system for farm combines and other large vehicles
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
SE530813C2 (sv) * 2007-01-31 2008-09-16 Tolerans Ab Förfarande och anordning vid en rotationshäftmaskin

Also Published As

Publication number Publication date
DE60225571T2 (de) 2009-04-23
DE60225571D1 (de) 2008-04-24
ES2303553T3 (es) 2008-08-16
PT1427395E (pt) 2008-05-20
EP1829530A2 (de) 2007-09-05
US20030054042A1 (en) 2003-03-20
EP1427395A1 (de) 2004-06-16
JP2010280687A (ja) 2010-12-16
DK1427395T3 (da) 2008-06-30
US20120087984A1 (en) 2012-04-12
US20090175951A1 (en) 2009-07-09
CY1108130T1 (el) 2014-02-12
CA2460436A1 (en) 2003-03-27
EP1427395B1 (de) 2008-03-12
US20070224279A1 (en) 2007-09-27
WO2003024424A1 (en) 2003-03-27
JP2005505568A (ja) 2005-02-24
EP1829530A3 (de) 2009-05-06
CA2460436C (en) 2011-05-10

Similar Documents

Publication Publication Date Title
ATE388690T1 (de) Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen
JP2005505568A5 (de)
BR0204214A (pt) Composição e, método para liberar um ciclopropeno
DK531885A (da) Fremgangsmaade til desinfektion og middel dertil
KR970027031A (ko) 일차 또는 이차 알콜의 산화방법
DE69819871D1 (de) Stabile zusammensetzungen enthaltend ein retinoid und ein antioxidierendes system auf enzymbasis
ATE179884T1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
BR9812562A (pt) Composição aquosa espessada, processo para limpeza de crostas de cal, e, uso de uma mistura ácida
AR064086A1 (es) Formulaciones liquidas de artropodicidas de carboxamida
DE60234420D1 (de) Haarbehandlungsmittel
ATE553746T1 (de) Verfahren zur herstellung eines dünnen films, thermolabile wirkstoffe enthaltend
NO20041509L (no) Rengjoringspreparat.
ATE330004T1 (de) Lagerungsstabile, flüssige zusammensetzung, welche laccase enthalten
ATE255881T1 (de) Zusammensetzungen aus unlöslichen filmbildenden polymeren und ihre verwendung
BR0112254A (pt) Lìquido para tratamento ácido e processo para tratamento de superfìcies de cobre
ATE449643T1 (de) Verfahren zur stabilisierung von peroxycarbonsäuren in tensidhaltigen dispersionen
AR018401A1 (es) Un material absorbente
DE602004007553D1 (de) Stabilisierung mit substituierten harnstoffen gegen farbabbau von körperpflegeprodukten
BR0213220A (pt) Processo de preparação de compostos de interação de uma substância ativa pouco solúvel em um meio aquoso com um suporte poroso, e, composto de interação de interação de uma substância ativa pouco solúvel em um meio aquoso em um suporte aquoso
WO2003057153A3 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
DE60316574D1 (de) Stabile augentropfen enthaltend latanoprost als wirkstoff
FR2343806A1 (fr) Composition detergente liquide avec adjuvant actif, ayant une stabilite au stockage amelioree
ATE250942T1 (de) Zusammensetzungen zur zersetzung von wasserstoffperoxid und verfahren zu deren verwendung
JP2022535170A (ja) ユースポイントにおける過酢酸の速やかな生成をもたらす高水準消毒剤としての組成物および方法
DE69815614D1 (de) Langsam abgebende Gelzusammensetzung für flüchtige Substanzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1427395

Country of ref document: EP